- **Title:** Prevalence of severe adverse events in health professionals after 1 receiving the first dose of the COVID-19 vaccination in Togo, March 2 2021.
- 3

**Short title:** Prevalence of severe adverse events in health professionals 4 after the COVID-19 vaccination in Togo, 2021. 5

#### Authors: 6

- Yao Rodion KONU<sup>1,2</sup>, Fifonsi Adjidossi GBEASOR-KOMLANVI<sup>1,2</sup>, Mouhoudine 7
- YERIMA<sup>3</sup>, Arnold Junior SADIO<sup>1,2</sup>, Martin Kouame TCHANKONI<sup>2</sup>, Wendpouire Ida 8
- Carine ZIDA-COMPAORE<sup>2</sup>, Josée NAYO-APETSIANYI<sup>4</sup>, Kossivi Agbélénbko 9
- AFANVI <sup>1,4</sup>, Sibabe AGORO <sup>1,4</sup>, Mounerou SALOU <sup>5</sup>, Dadja Essoya LANDOH <sup>6</sup>, 10
- Atany B. NYANSA <sup>3</sup>, Essohanam BOKO<sup>7</sup>, Moustafa MIJIYAWA <sup>4,7</sup>, Didier Koumavi 11 EKOUEVI 1,2,8 # 12
- 1. Université de Lomé, Département de Santé Publique, Lomé, Togo 13
- 2. Centre Africain de Recherche en Epidémiologie et en Santé Publique 14 (CARESP), Lomé, Togo 15
- Ministère de la Santé et de l'Hygiène Publique, Service de phramacovigilance 16 Lomé. Togo 17 18
  - 4. Ministère de la Santé et de l'Hygiène Publique, Lomé, Togo
- 5. Université de Lomé, Laboratoire de Biologie Moléculaire et d'Immunologie 19 (BIOLIM), Lomé Togo 20
- 6. World Health Organization (WHO), Country Office of Togo, Lomé, Togo 21
- 7. Université de Lomé, Faculté des Sciences de la Santé, Lomé, Togo 22
- 23 8. Centre Inserm, 1219, Institut de Santé Publique et de Développement et Université de Bordeaux, Bordeaux, France 24 25
- 26 Corresponding author #
- Didier Koumavi EKOUEVI 27
- 28 Université de Lomé
- 29 Cell: 00228 9313 6655
- Mail: didier.ekouevi@gmail.com 30
- 31
- 32

#### 33 Abstract:

Introduction: Covid-19 vaccines can cause adverse events (AE) that can lead to increased hesitation or fear of vaccination. This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals (HPs) vaccinated with COVISHIELD<sup>TM</sup> vaccine in Togo.

Methods: A cross-sectional study was conducted from March 13<sup>th</sup> to 19<sup>th</sup>, 2021 in Togo among HPs who received the first dose of vaccine. An online self-administered questionnaire was used to collect data on sociodemographic characteristics and vaccination. SAEs were defined as one resulting in hospitalization, medical consultation, or inability to work the day following the administration of the vaccine. Regression analysis were performed to assess factors associated with SAEs.

Results: A total of 1,639 HP (70.2% male) with a median age [IQR] of 32 years [27-44 40] participated. At least one AE was reported among 71.6% (95%CI= [69.3-73.8]). 45 The most commonly reported AEs were pain at the injection site (91.0%), asthenia 46 (74.3%), headache (68.7%), soreness (55.0%), and fever (47.5%). An increased libido 47 was also reported in 3.0% of HP. Among HP who experienced AEs, 18.2% were unable 48 to go to work the day after vaccination, 10.5% consulted a medical doctor, and 1.0% 49 were hospitalized. The SAE prevalence was 23.8% (95%CI= [21.8-25.9]). Being <30 50 years (aOR=5.54; p<0.001), or 30-49 years (aOR=3.62; p<0.001) and being female 51 (aOR=1.97; p<0.001) were associated with SAEs. 52

Conclusion: Despite the occurrence of SAEs, current data collected in Togo about
 adverse events are reassuring with COVISHIELD<sup>™</sup> vaccine and how they could be
 managed.

Keywords: Severe adverse event, COVID-19, vaccine, prevalence, health
 professionals, Togo.

# 59 Key points:

- The prevalence of severe adverse events (SAEs) after COVID-19 vaccination
   was high among health professionals in Togo, especially in the youths (under
   30years).
- Despite the occurrence of SAEs, current data collected in Togo about adverse
   events are reassuring with COVISHIELD(TM) vaccine and provide information
   about how the could be managed.
- 66
- 67
- 68

# 69 **1. Introduction**

Coronavirus disease 2019 (COVID-19) was first described in China in December 2019
[1] and resulted in the declaration of a pandemic in January 2020 [2]. As of March 24,
2021, more than 120 million cases of COVID-19 infections, with more than 2 million
deaths, were reported worldwide [3].

No cure or vaccine was available until December 2020. Therefore, controlling the infection to prevent the spread of COVID-19 was considered the only intervention [4]. Several social and public health risk mitigation measures were proposed and implemented to reduce the spread of the pandemic. These measures include individual measures (frequent hand hygiene, physical distancing, and use of masks) and physical and social distancing measures (reduction of mass gatherings, and promotion of telecommuting) [5].

However, given that vaccination has been identified as a relevant intervention for 81 stopping epidemics and fighting against infectious diseases, research on a COVID-19 82 vaccine has been promoted. At an early stage of this pandemic, the World Health 83 Organization (WHO) and the Global Alliance for Vaccines and Immunization (Gavi) 84 launched a pooled procurement mechanism for new COVID-19 vaccines called the 85 COVAX Facility to ensure fair, global and equitable access to vaccines [6]. This facility 86 also aims to end the acute phase of the COVID-19 pandemic by accelerating the 87 development of safe and effective vaccines against COVID-19 and contributing to the 88 development of production capacity [7]. The first vaccines received the Emergency 89 Use Listing from WHO in December 2020 [8]. 90

Like many African countries, Togo has joined the COVAX facility and participated in COVID-19 vaccine procurement process [6]. On March 7, 2021, Togo received the first

allocation of 156,000 doses of the SII-AstraZeneca (COVISHIELD<sup>™</sup>) vaccine [9]. 93 COVISHIELD<sup>™</sup> was developed by AstraZeneca and Oxford University and produced 94 by the Pune-based Serum Institute of India [10]. It is a viral vector vaccine (ChAdOx1-95 S) that was approved for emergency use by the WHO [11]. In Togo, the vaccination 96 campaign was launched on March 10<sup>th</sup>, 2021. According to the National Deployment 97 and Vaccination Plan for COVID-19 vaccines, the priority target was 35,119 health 98 professionals (HP) followed by people over 50 years of age and those living with at 99 least one comorbidity condition (hypertension, diabetes, heart disease etc.) [12]. These 100 groups were targeted because they are at greater risk of exposure to COVID-19 or 101 102 because they have an increased risk of death in case of infection.

Vaccination against COVID-19 is an essential pillar for controlling the pandemic in addition to other infection risk mitigation measures included in test, treat, track (T3) approach. In Togo, vaccination against COVID-19 is implemented at a time when the country is experiencing an epidemic peak with more than 600 cases per week since February 1<sup>st</sup>, 2021 compared to 100 cases per week in December 2020 [13]. As of March 24<sup>th</sup>, 2021, 9147 COVID-19 infections cases, of which, 105 deaths, have been reported in Togo [14].

Despite the awareness campaign on the importance of vaccination, several factors contribute to limiting the adherence of the population to this intervention. These include: i) the relative speed of discovery and availability the of vaccines, ii) the use of new technologies never before deployed in humans, and iii) the lack of hindsight regarding the safety of vaccines that are available.

As a result, false information has been circulating about these new vaccines and has contributed to the growing anxiety and vaccine hesitancy associated with a fear of

occurrence of long-term adverse events. In addition, the suspension of the
AstraZeneca vaccine in Europe after the occurrence of thrombosis cases has amplified
psychosis with popular pressure to stop the vaccination campaign in Africa including
Togo.

On March 11 and 12, Togo conducted a large-scale vaccination program against COVID-19 for HP and 18,249 were vaccinated [15]. In parallel with the surveillance of adverse events following immunization which is ensured by the pharmacovigilance service of the Ministry of Health, this study was launched to quickly document adverse events to reassure the population. Our objective was to estimate the prevalence of severe adverse events (SAEs) and their associated factors among HPs in Togo.

### 128 **2. Methods**

### 129 **2.1. Study design and setting**

This study was a cross-sectional study that was conducted from March 13 to 19, 2021in Togo.

Togo is a country of West Africa that covers an area of 56,800 km<sup>2</sup> with an average density of 145 inhabitants per square kilometer [16]. The population was 8.08 million in 2019, of which 50.2% were women [17]. Most of the population is young (60% of Togolese are under 25 years of age), and lives in rural areas (62%) [17]. Togo's health system has a three-level pyramid structure: central, intermediate and peripheral levels. Administrative and healthcare delivery components are associated with every level.

### 138 **2.2. Study population and sample size**

The target population included all HPs who received the first dose of the COVISHIELD<sup>TM</sup> vaccine during the first phase of the vaccination campaign in Togo. For the purpose of this study, a health professional was defined as a professional who works or is affiliated with the health sector, including workers from health administration and logistics, clinical settings, and community health workers. The inclusion criteria for eligible participants were: (i) being a health professional aged 18 years and older; and (ii) having received the first dose of vaccine.

The sample size of participants was calculated using a single proportion population formula with a 95% confidence level. In the absence of previous studies on the severity of the adverse events of the vaccine against COVID-19, we hypothesized that 10% of the participants would experience at least one severe adverse event with a 2% margin

error and a 10% nonresponse rate. The minimum number of participants wasestimated at 960.

### 152 **2.3. Data collection**

A multiple-choice questionnaire was developed using items from a questionnaire of the 153 Pharmacovigilance Department of the Togo Ministry of Health and from previous 154 related studies found in the literature [18,19]. The questionnaire consisted of two main 155 sections on sociodemographic and professional characteristics (age, sex, marital 156 status, working place) and vaccination (date, process, confidence in the vaccine 157 158 efficacy, occurrence of adverse events and likelihood of getting the second dose). The self-administered questionnaire was made available using a free online platform 159 through the internal communication networks of the Ministry of Health. The data 160 collection process began two days after the end of the first phase of the vaccine 161 campaign which targeted HPs in Togo. 162

#### 163 **2.4. Definition of the outcome variable**

The main outcome was the severity of reported adverse events. Adverse events were grouped into three categories: severe (presence of adverse events resulting in selfreported hospitalization, seeking medical consultation, and inability to work the day following the administration of the vaccine), moderate (presence of adverse events without hospitalization, consultation or impact on working ability), and no side effects.

169

### 9 **2.5. Data management and statistical analysis**

Data were imported into a Microsoft Excel database for data cleaning. Descriptive statistics were performed, and the results are presented using frequency tabulations and percentages for categorical variables. Quantitative variables are presented as medians with their interquartile range (IQR). Proportions were compared using Chisquare test or Fisher's exact test when appropriate. Prevalence of SAEs was estimated
with its 95% confidence interval (95% CI).

176 Univariable and multivariable logistic model regression were performed to assess factors associated with SAEs. For model building, characteristics that had a p-value 177 <0.20 in univariable analysis were considered for the full multivariable models, which 178 were subsequently finalized using a stepwise, backward elimination approach (p-value 179 <0.05). Predictor variables were selected as those found to be relevant according to 180 the literature review. Sensitivity analysis was performed based on a second definition 181 of SAEs which considered only self-reported hospitalization or seeking medical 182 consultation. Data analysis were performed using R<sup>©</sup> version 4.0.1 software, and the 183 level of significance was set at 5%. 184

185

### 5 2.6. Ethical considerations

Ethical approval was obtained from the 'Comité de Bioéthique de Recherche en Santé' (Bioethics Committee for Health Research) from the Togo Ministry of Health (No. 01/2021/CBRS). An introductory question was asked to ensure participants' consent.

### 190 **3. Results**

#### 191 **3.1. Sociodemographic characteristics of health professionals**

A total of 1,639 HPs (70.2% male) who had received the first dose of the vaccine
responded to the questionnaire. This sample represents 4.6% of the HPs vaccinated
in Togo.

The median age [IQR] of the participants was 32 years [27-40]. Approximately half (45.8%) of the participants resided or practiced in the *Grand-Lomé* region and 54.7% were married (Table 1).

### 198 **3.2. Prevalence of adverse events**

Among the 1,639 participants, 1174 (71.6%, 95% CI = [69.3-73.8]) reported at least one side effect. The most commonly reported adverse events were pain at the injection site (91.0%), asthenia (74.3%), headache (68.7%), body aches (55.0%), and fever (47.5%). An increase in libido was also reported in 3.0% of the participants (Figure 1). Of the participants who experienced adverse events, 18.2% were unable to go to work the day after vaccination, 10.5% consulted a medical doctor, and 1.0% were hospitalized. Thus, the prevalence of SAEs was 23.8% (95% CI = [21.8-25.9]).

## 206 **3.3. Post vaccination treatment**

Overall, medication use after vaccination was higher among participants with SAEs (p<0.001). The use of analgesics by participants with SAE was 62.3% vs 39.0% for participants with moderate events and 5.2% for those reporting no events (Table 2).

#### 210 **3.4. Perception after vaccination**

A total of 67.5% of survey participants expressed concern about long-term adverse events, and this concern was more pronounced among women than men (74.2% vs. 64.7%, p<0.001). Approximately one out of ten participants (10.9%) said they were not ready to take the second dose of the vaccine (Table 3).

# **3.5.** Factors associated with the occurrence of severe adverse events

In univariate analysis, factors associated with the occurrence of SAEs included being under 30 years of age (OR=4.74; p<0.001), or 30-49 years of age (OR=3.00; p<0.001) and being female (OR=2.07; p<0.001). The same factors were associated with the occurrence of SAEs in multivariate analysis (Table 4).

Using the second definition of SAEs, the prevalence of SAEs was estimated at 10.6% (95% CI = [9.2-12.2]); the factors associated with the occurrence of SAE were the same both in univariate and in multivariate analysis (under 30 years of age aOR=2.23; p=0.049; 30-49 years of age, aOR=2.73, p=0.016 and being female, aOR=2.01, p<0.001).

225

# 227 **4. Discussion**

This is the first study in Africa to report SAEs after vaccination with the COVISHIELD<sup>™</sup> vaccine in the context of COVID-19 among HPs. We included 4.6% of healthcare professionals vaccinated in Togo. SAEs were reported among 23.8% of participants in the current study. Most adverse events reported were mild or severe and compared with those reported in trials of AstraZeneca [20,21]. However, this study clearly shows that the odds of experiencing SAEs after vaccination against COVID-19 are higher in younger people and women compared to older adults and men, respectively.

Based on our operational definition, approximately one-quarter of participants reported 235 SAEs. This value could be overestimated since because we included the inability to 236 work the day after vaccination. If we consider only hospitalization and consultation of 237 a medical doctor after vaccination, approximately 12.0% presented SAEs. In a single-238 blind, randomized, controlled, phase 2/3 trial (COV002), in the United Kingdom (UK), 239 as of October 26, 2020, 13 serious adverse events occurred during the study period, 240 but none of those were considered to be related to the study vaccine [22]. The interim 241 analysis of the efficacy and safety of the ChAdOx1 nCoV-19 vaccine includes data 242 from four ongoing blinded, randomized, controlled trials performed across three 243 countries including the UK, Brazil and South Africa, and was reported in January 2021 244 [20]. In this analysis, 175 SAEs occurred in 168 participants, of which three events 245 were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, 246 one in the control group, and one in a participant who remained masked to group 247 allocation. 248

249 Several definitions exist to classify adverse events according to their severity. For 250 example, in the COV002 trial, in the UK, SAEs were defined as substantial limitations 251 in activity and medical intervention or the requirement of therapy [22].

We did not include, the use of medication in our definition, given that the study population was included HPs who have easy access to medication and a proven tendency to self-medicate [23,24]. Interpretations of the severity of adverse events must take into account the definition we adopted.

In our study, SAEs were more common in younger people than in people aged 50 256 257 years and older. The younger the subject was, the more severe the adverse events tended to be. This trend has been reported by Oxford COVID Vaccine Trial Group and 258 seems to be related to an exaggerated immune response in young subjects [22]. In 259 other countries, severe events following the COVISHIELD<sup>™</sup> vaccine have been 260 observed more in subjects under 55 years of age, which has prompted France among 261 other countries to exclusively recommend this vaccine for subjects aged 55 years and 262 older. In Togo, such recommendation is difficult to apply given there is no other vaccine 263 available to date. 264

Adverse events after vaccination were more pronounced in women. This observation is not unusual for vaccines in general [25] and seems to be consistent with data in the literature about COVID-19 vaccines [26,27]. More SAEs in women have been reported in other settings and appear to be related to a stronger immune response triggered by estrogen [25].

270 Most reported adverse events with the COVID-19 vaccine were mild. A sore arm was 271 the most common, and others included headache, tiredness, and a mild flu-like 272 symptoms [28,29]. Similar adverse events were reported in our study. However, in our 13 study, an increase in libido was unexpectedly reported by 3.0% of HPs in both men
and women. Among all UK spontaneous reports received between March 4,2021 and
March 14,2021 for COVID-19 Oxford University/AstraZeneca vaccine, one case of
increased libido, one of decreased libido and six cases of loss of libido were mentioned
[30]. This information should be investigated to demonstrate an association with
vaccination.

279 Concerning the perception/intention after the first dose of vaccine, two thirds of the 280 participants expressed concern about long-term adverse events, and one out of ten 281 declared they were not ready to take the second dose of the vaccine. These results 282 could be explained by several concerns about ChAdOx1 nCoV-19 which arose in 283 Europe and some African countries and resulted in the temporarily suspension the 284 administration of this vaccine [31].

This study presents some limitations. We cannot exclude selection bias due to our sampling method. Another limitation is that data collection was based on a declarative approach. However, given that the participants were HPs, the reported effects are probably consistent with reality.

Finally, we used an operational definition to define SAE. This is a composite variable including absence from work the day after vaccination, medical consultation and hospitalization due to adverse events. This definition probably led to an overestimation of SAE, but this operational definition seems appropriate in the Togolese context.

Based on these results of a high prevalence of SAEs in young people, systematic prescription of antalgics or antipyretics could be proposed to young people who are eligible to be vaccinated. Careful monitoring of SAEs should be performed in younger

people under 50 years of age. If another vaccine becomes available in Togo, the
 COVISHIELD<sup>TM</sup> vaccine should be reserved for older adults.

A cohort study is therefore needed for a follow-up of HPs to better document the occurrence of long-term adverse events. The results from the present study are useful for designing a sensitization program in order to reassure the general population about COVID-19 vaccination. At this stage, there is no reported sign in link with thrombosis.

#### 302 5. Conclusion

In conclusion, despite the occurrence of SAEs, vaccination against COVID-19 remains
 an important strategy to fight against this pandemic. Current data collected in Togo are
 reassuring about adverse events and how they could be managed.

## 307 **Declarations:**

# 308 i. **Funding**: Not applicable

ii. Conflicts of interest/Competing interests: The authors declare that they have
 no competing interests. DEL works for the World Health Organization, Togo
 country office. The authors are solely responsible for the views expressed in
 this manuscript and do not necessarily represent the decisions, policies or views
 of the World Health Organization.


- 314 iii. Availability of data and material: Available on request to the corresponding315 author.
- 316 iv. Code availability: Not applicable
- v. Ethics approval: This study obtained ethical approval from the 'Comité de Bioéthique de Recherche en Santé' (Bioethics Committee for Health Research)
   from the Togo Ministry of Health (No. 01/2021/CBRS).
- vi. **Consent to participate**: informed consent was collected prior to inclusion.
- 321 vii. **Consent for publication:** Not applicable

# 323 References

- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–33.
- World Health Organization (WHO). Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [Internet]. [cited 2021 Mar 29].
   Available from: https://www.who.int/news/item/30-01-2020-statement-on-thesecond-meeting-of-the-international-health-regulations-(2005)-emergencycommittee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).
- World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard
  [Internet]. [cited 2021 Mar 24]. Available from: https://covid19.who.int
- Bruinen de Bruin Y, Lequarre A-S, McCourt J, Clevestig P, Pigazzani F, Zare
  Jeddi M, et al. Initial impacts of global risk mitigation measures taken during the
  combatting of the COVID-19 pandemic. Saf Sci. 2020 Aug;128:104773.
- World Health Organization (WHO). Overview of Public Health and Social
  Measures in the context of COVID-19 [Internet]. [cited 2020 Jun 19]. Available
  from: https://www.who.int/publications-detail-redirect/overview-of-public-healthand-social-measures-in-the-context-of-covid-19.
- 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine
   Global Access Facility [Internet]. [cited 2021 Mar 24]. Available from:
   https://www.who.int/news/item/24-08-2020-172-countries-and-multiple candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility
- World Health Organization (WHO). COVID-19 vaccines [Internet]. [cited 2021
   Mar 24]. Available from: https://www.who.int/emergencies/diseases/novel coronavirus-2019/covid-19-vaccines
- World Health Organization (WHO). WHO issues its first emergency use
   validation for a COVID-19 vaccine and emphasizes need for equitable global
   access [Internet]. [cited 2021 Mar 26]. Available from:
- https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global access
- Global Alliance for Vacccination and Immunization (GAVI). COVAX roll-out Togo [Internet]. [cited 2021 Mar 24]. Available from: https://www.gavi.org/covax vaccine-roll-out/togo
- Staff S. Covid-19: India looking at all 'serious' side effects amid safety concerns about AstraZeneca vaccine [Internet]. Scroll.in. https://scroll.in; [cited 2021 Mar 26]. Available from: https://scroll.in/latest/989440/covid-19-india-looking-at-allserious-side-effects-amid-safety-concerns-about-astrazeneca-vaccine

- World Health Organization (WHO). WHO recommendation Serum Institute of India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVISHIELD<sup>™</sup>
   [Internet]. WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). 2021 [cited 2021 Mar 26].
   Available from: https://extranet.who.int/pqweb/vaccines/covid-19-vaccinechadox1-s-recombinant-covishield
- 12. COVID-19 national deployment and vaccination plan: Submission and review
   process, 29 January 2021 [Internet]. [cited 2021 Mar 30]. Available from:
   https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-NDVP country\_plans-2021.1
- 13. République Togolaise, Ministère de la Santé, de l'Hygiène Publique et de
  l'Accès Universel aux Soins. Epidémie de COVID-19 au Togo-Rapport de
  situation N°381 au 28 mars 2021. 2021; 10p.
- 14. République Togolaise. COVID-19 [Internet]. COVID 19. [cited 2021 Mar 24].
   Available from: https://covid19.gouv.tg/
- 15. République Togolaise. Ministère de santé, de l'hygiène publique et de l'accès
  universel aux soins. Vaccination du personnel de santé du pays contre la
  COVID-19 (Bulletin d'information N°2). 2021. 4p.
- World Bank, Data Bank. CountryProfile [Internet]. [cited 2021 Mar 26]. Available
   from:
- 382https://databank.worldbank.org/views/reports/reportwidget.aspx?Report\_Name=383CountryProfile&Id=b450fd57&tbar=y&dd=y&inf=n&zm=n&country=TGO
- 17. République Togolaise, Direction Générale de la Statistique et de la Comptabilité
  Nationale du Togo (DGSCN). Résultats définitifs du 4ième Recensement
  Général de la Population et de l'Habitat (4ième RGPH4). Lomé : DGSCN ; 2010,
  66p. Disponible sur : https://inseed.tg/download/2958/.
- 18. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines:
   comparison of biological, pharmacological characteristics and adverse effects of
   Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021
   Feb;25(3):1663–9.
- 19. D'Alessandro D, Ciriminna S, Rossini A, Bossa MC, Fara GM. Requests of
   medical examinations after pneumococcal & influenza vaccination in the elderly.
   Indian J Med Res. 2004 May;119 Suppl:108–14.
- 20. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.
  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
  SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,
  South Africa, and the UK. Lancet Lond Engl. 2021;397(10269):99–111.
- Torjesen I. Covid-19: First UK vaccine safety data are "reassuring," says
   regulator. BMJ. 2021 Feb 8;372:n363.

- Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens
  DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine
  administered in a prime-boost regimen in young and old adults (COV002): a
  single-blind, randomised, controlled, phase 2/3 trial. Lancet Lond Engl.
  2021;396(10267):1979–93.
- 23. Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk Factors of Healthcare
  Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a
  Designated Hospital of Wuhan in China. Clin Infect Dis Off Publ Infect Dis Soc
  Am. 2020 Nov 19;71(16):2218–21.
- 410 24. Sadio AJ, Gbeasor-Komlanvi FA, Konu RY, Bakoubayi AW, Tchankoni MK,
  411 Bitty-Anderson AM, et al. Assessment of self-medication practices in the context
  412 of the COVID-19 outbreak in Togo. BMC Public Health. 2021 Jan 6;21(1):58.
- Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, vom Steeg L, et al. Ageassociated changes in the impact of sex steroids on influenza vaccine
  responses in males and females. Npj Vaccines. 2019 Jul 12;4(1):1–12.
- 416 26. Gee J. First Month of COVID-19 Vaccine Safety Monitoring United States,
  417 December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep [Internet].
  418 2021 [cited 2021 Mar 26];70. Available from:
  419 https://www.ede.gov/mmwr/volumes/20/wr/mm7008e2.htm
- 419 https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm
- 27. Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman
  AB, et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA
  [Internet]. 2021 Mar 8 [cited 2021 Mar 26]; Available from:
- 423 https://jamanetwork.com/journals/jama/fullarticle/2777417
- 424 28. World Health Organization (WHO). Coronavirus disease (COVID-19): Vaccines
  425 safety [Internet]. [cited 2021 Mar 26]. Available from: https://www.who.int/news426 room/q-a-detail/coronavirus-disease-(covid-19)-vaccines-safety
- 427 29. US Centers for Diseases Control and Prevention (US CDC). What to Expect
  428 after Getting a COVID-19 Vaccine [Internet]. Centers for Disease Control and
  429 Prevention. 2021 [cited 2021 Mar 26]. Available from:
  430 https://www.ede.gov/coropovirus/2019.peov/vaccinos/ovpact/after.html
- 430 https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html
- 30. Government of the United Kingdom. Assests publishing service. COVID-19
  vaccine AstraZeneca analysis print. 2021. [Cited 26/03/2021]. Available from:
  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/att
  achment\_data/file/972833/COVID-19\_AstraZeneca\_Vaccine\_Analysis\_Print.pdf.
- 435 31. World Health Organization (WHO). WHO statement on AstraZeneca COVID-19
  436 vaccine safety signals [Internet]. [cited 2021 Mar 26]. Available from:
  437 https://www.who.int/news/item/17-03-2021-who-statement-on-astrazeneca438 covid=10-vaccino-safety signals
- 438 covid-19-vaccine-safety-signals
- 439
- 440



	Frequency	Proportion (%)		
Age (years), Median (IQR)	32	(27-40)		
Age (years)				
<30	634	38.7		
30-49	862	52.6		
≥50	143	8.7		
Sex				
Female	488	29.8		
Male	1151	70.2		
Health region				
Grand-Lomé	751	45.8		
Maritime	243	14.8		
Plateaux	161	9.8		
Centrale	104	6.4		
Kara	274	16.7		
Savanes	106	6.5		
Marital status				
Single/Widowed/Divorced	742	45.3		
Married	897	54.7		

**Table 1**. Sociodemographic characteristics of health professionals vaccinated against COVID-19in Togo, 2021 (n = 1,639)

IQR: interquartile range

	Adverse events after COVID-19 vaccination					
	None	Moderate	Severe	Overall	P	
	(n = 442)	(n = 807)	(n = 390)	(n = 1,639)	-	
Analgesics, n (%)	23 (5.2)	315 (39.0)	243 (62.3)	581 (35.4)	<0.001*	
Antipyretics, n (%)	15 (3.4)	207 (25.7)	181 (46.4)	403 (24.6)	<0.001*	
NSAIDs <sup>\$</sup> , n (%)	10 (2.3)	82 (10.2)	65 (16.7)	157 (9.6)	<0.001*	
Antihistamines, n (%)	1 (0.2)	23 (2.9)	43 (11.0)	67 (4.1)	<0.001**	
Vitamin C, n (%)	1 (0.2)	19 (2.4)	17 (4.4)	37 (2.3)	<0.001**	
Herbal medicines/infusions, n (%)	0 (0.0)	12 (1.5)	14 (3.6)	26 (1.6)	<0.001**	

**Table 2**. Use of medication after vaccination against COVID-19 according to the severity ofadverse events among health professionals, Togo, 2021

<sup>\$</sup>NSAIDs: non-steroidal anti-inflammatory drugs

\*Chi-squared test; \*\*Fisher test

	Female	Male	Overall	р
	(n = 488)	(n = 1,151)	(n = 1,639)	
Afraid of long-term adverse events				<0.001*
No	126 (25.8)	406 (35.3)	532 (32.5)	
Yes	362 (74.2)	745 (64.7)	1107 (67.5)	
Regret to have been vaccinated				<0.001*
No	347 (71.1)	923 (80.2)	1270 (77.5)	
Yes	141 (28.9)	228 (19.8)	369 (22.5)	
Ready for the second dose				0.004*
Hesitation	201 (41.2)	391 (34.0)	592 (36.1)	
No	59 (12.1)	119 (10.3)	178 (10.9)	
Yes	228 (46.7)	641 (55.7)	869 (53.0)	

**Table 3.** Perceptions among health professionals after vaccination against COVID-19, Togo,2021

\*Chi-squared test

			Binary logistic model regression					
	Preva	Prevalence —		Univariable		Multivariable		
	n	%	OR	95%CI	р	aOR	95%CI	р
Age (years)								
<30	192	30.3	4.74	2.67-9.22	<0.001	5.54	2.95-11.42	<0.001
30-49	186	21.6	3.00	1.69-5.83	<0.001	3.62	1.94-7.41	<0.001
≥50	12	8.4	1.00	-	-	1.00	-	-
Sex								
Female	164	33.6	2.07	1.63-2.63	<0.001	1.97	1.53-2.54	<0.001
Male	226	19.6	1.00	-	-	1.00	-	-
Having comorbidities								
Yes	55	21.9	0.88	0.63-1.21	0.447	1.12	0.70-1.73	0.628
No	335	24.1	1.00	-	-	1.00	-	-
History of COVID-19 infection								
No	339	23.6	1.07	0.64-1.88	0.815	0.98	0.57-1.75	0.934
No answer	9	36.0	1.94	0.72-5.08	0.182	1.90	0.69-5.08	0.206
Yes	18	22.5	1.00	-	-	1.00	-	-

Table 4. Factors associated with severe adverse events after COVID-19 vaccination among health professionals in Togo, 2021

OR: Odds ratio; aOR: adjusted Odds ratio; 95%CI: 95% confidence interval